Chinese trial tests two drug cocktails for rare blood cancer
NCT ID NCT02844322
Summary
This study compared two different drug combinations for people newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. Thirty-five patients in China received either a rituximab-based regimen or a bortezomib-based regimen, along with two other standard drugs. The goal was to see which combination was better at controlling the disease and preventing it from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shuhua Yi
Tianjin, 300020, China
Conditions
Explore the condition pages connected to this study.